Global Information
회사소개 | 문의

중국의 부데소나이드(Budesonide) 시장

Investigation Report on China Budesonide Market, 2018-2022

리서치사 China Research and Intelligence
발행일 2018년 06월 상품 코드 296859
페이지 정보 영문 30 Pages
가격
US $ 2,200 ₩ 2,506,600 Unprintable PDF (Single User License)
US $ 3,300 ₩ 3,760,000 Printable & Editable PDF (Enterprisewide License)


중국의 부데소나이드(Budesonide) 시장 Investigation Report on China Budesonide Market, 2018-2022
발행일: 2018년 06월 페이지 정보 : 영문 30 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

중국의 부데소나이드(Budesonide) 시장을 조사 분석했으며, 발전 역사, 시장 규모, 시장 점유율, 가격, 시장 전망 등의 정보를 정리하여 전해드립니다.

제1장 부데소나이드 관련 개념

  • 부데소나이드의 적응
  • 중국의 부데소나이드 발전 역사
  • 중국의 부데소나이드 특허 현황과 승인 정보

제2장 중국의 부데소나이드 매출액

  • 부데소나이드 매출액
  • 부데소나이드 판매량
  • 중국의 제형별 부데소나이드 매출액

제3장 중국의 부데소나이드 주요 제조업체 분석

  • 부데소나이드 주요 제조업체의 시장 점유율 분석
  • AstraZeneca
  • Synmosa Biopharma Corporation
  • Lunan Better Pharmaceutical Co., Ltd.
  • Orion Pharma
  • Shanghai Sine Pharmaceutical Laboratories Co., Ltd.

제4장 중국 시장의 제조업체별 부데소나이드 가격

  • AstraZeneca
  • Synmosa Biopharma Corporation
  • Lunan Better Pharmaceutical Co., Ltd.
  • Orion Pharma
  • Shanghai Sine Pharmaceutical Laboratories Co., Ltd.

제5장 중국의 부데소나이드 시장 전망

  • 시장 규모 예측
  • 시장 동향 예측
LSH 18.07.05

영문목차

Every year, nearly 300 million people in China, including over 50 million cough patients, get infected with respiratory diseases. It is estimated that the number of asthma patients in China has exceeded 20 million. Inhaled corticosteroids are suitable for the long-term treatment of bronchial asthma and can avoid all kinds of adverse reactions caused by systemic use of corticosteroids. At present, the main inhaled corticosteroids used in clinical practice are Budesonide, Fluticasone and Beclomethasone.

In the 1990s, Budesonide was successfully developed by AstraZeneca to be used for the treatment of non-corticosteroid dependent or corticosteroid-dependent bronchial asthma and chronic obstructive pulmonary disease. In Jun. 1997, Budesonide aerosol was approved by the FDA.

In 1994, China approved the import of Budesonide. In 1995, Astra (Wuxi) Pharmaceutical was approved to manufacture and sell Budesonide in China. Budesonide has been developing rapidly since it entered the Chinese market. Its annual sales increased from approximately CNY 100 million in 2007 to approximately CNY 1.2 billion in 2017 with the CAGR from 2007 to 2017 up to 27.7%. There is a high demand for Budesonide in China. The majority of Budesonide currently sold on the market are manufactured by AstraZeneca, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical Co., Ltd., Orion Pharma and Shanghai Sine Pharmaceutical Laboratories Co., Ltd. In terms of sales, AstraZeneca has the highest market share, accounting for more than 90% of the Chinese market in 2017.

Owing to the aggravating environmental pollution and ageing population, China will see a rising incidence of respiratory diseases from 2018 to 2012, which will lead to an ever-expanding Budesonide market.

Topics Covered:

  • Development history of Budesonide in China
  • Size of Chinese Budesonide market
  • Market share of major Budesonide manufacturers in China
  • Market share of various dosage forms of Budesonide in China
  • Budesonide prices on the Chinese market
  • Prospects of Chinese Budesonide Market, 2018-2022

Table of Contents

Table of Contents

1 Relevant Concepts of Budesonide

  • 1.1 Indications of Budesonide
  • 1.2 Development History of Budesonide in China
  • 1.3 Patent Status and Approval Information of Budesonide in China

2 Sales of Budesonide in China, 2013-2017

  • 2.1 Sales Value of Budesonide
    • 2.1.1 Sales Value of Budesonide in China
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Budesonide
    • 2.2.1 Sales Volume of Budesonide in China
    • 2.2.2 Sales Volume by Regions
  • 2.3 Sales of Various Dosage Forms of Budesonide in China,2013-2017
    • 2.3.1 Suspensions
    • 2.3.2 Sprays
    • 2.3.3 (Powder) Aerosols

3 Analysis on Major Budesonide Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Budesonide Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 AstraZeneca
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of AstraZeneca's Budesonide in China
  • 3.3 Synmosa Biopharma Corporation
  • 3.4 Lunan Better Pharmaceutical Co., Ltd.
  • 3.5 Orion Pharma
  • 3.6 Shanghai Sine Pharmaceutical Laboratories Co., Ltd.

4 Several Manufacturers' Budesonide Prices on the Chinese Market, 2017-2018

  • 4.1 AstraZeneca
  • 4.2 Synmosa Biopharma Corporation
  • 4.3 Lunan Better Pharmaceutical Co., Ltd.
  • 4.4 Orion Pharma
  • 4.5 Shanghai Sine Pharmaceutical Laboratories Co., Ltd.

5 Prospects of Chinese Budesonide Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Market Trend

Selected Charts

  • Chart Patent Status of Budesonide in China
  • Chart Governmental Approval of Budesonide in China
  • Chart Sales of Budesonide in China
  • Chart Sales Value of Budesonide in China, 2013- 2017
  • Chart Sales Value of Budesonide in Parts of China, 2013-2017
  • Chart Sales Volume of Budesonide in China, 2013- 2017
  • Chart Market Share of Top 5 Budesonide Manufacturers in Sales Value, 2013-2017
  • Chart Market Share and Sales Value of AstraZeneca's Budesonide in China, 2013-2017
  • Chart Market Share and Sales Value of Synmosa's Budesonide in China, 2013-2017
  • Chart Market Share and Sales Value of Lunan Better's Budesonide in China, 2013-2017
  • Chart Sales Value and Market Share of Budesonide Suspensions in China, 2013-2017
  • Chart Sales Value and Market Share of Budesonide Sprays in China, 2013-2017
  • Chart Prices of AstraZeneca's Budesonide in Several Chinese Cities, 2017-2018
  • Chart Prices of SYNMOSA's Budesonide in Several Chinese Cities, 2017-2018
  • Chart Prices of Lunan Better's Budesonide in Several Chinese Cities, 2017-2018
  • Chart Forecast on Sales Value of Budesonide in China, 2018-2012
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research